Journal of Analytical Research in Clinical Medicine (Jun 2015)

Levamisole as an adjuvant to hepatitis B vaccination in patients with chronic kidney disease

  • Mohammad-Hossein Somi,
  • Mohammad-Reza Ardalan,
  • Majid Moghadaszadeh,
  • Masoud Shirmohamadi,
  • Reza Piri,
  • Mohammad Naghavi-Behzad

DOI
https://doi.org/10.15171/jarcm.2015.013
Journal volume & issue
Vol. 3, no. 2
pp. 87 – 93

Abstract

Read online

Introduction: High risk of blood-borne infections is one of the problems of patients with chronic kidney disease (CKD), above which, there is hepatitis B. One of the ways to prevent this disease is vaccination against hepatitis B besides observing standard precautions. Lack of response to vaccine in uremic patients has been reported up to 33.0%. The aim of this study was to investigate the effect of levamisole as an adjuvant in improving vaccination response in patients suffering from CKD. Methods: In this cohort study, 30 patients suffering from the chronic renal disease who had undergone levamisole plus hepatitis B vaccine were included in the study as exposed group (Group A). Then 30 equivalent patients who had just underwent hepatitis B vaccination were in the study as a unexposed group (Group B). Antibody titer against hepatitis B virus (HBV) was compared between two groups monthly, then data was analyzed. Results: Mean age of all investigated patients was 58.1 ± 14.9 years old, and it ranged from 26 to 82. 23 patients (38.3%) were female, and 37 patients (61.7%) were male. None of the patients in both groups had a history of previous hepatitis B vaccination. Mean antibody titer was higher in group A than that of the group B after the first and second stages of hepatitis B vaccination. However, the difference between two groups was not statistically significant (P = 0.14 and P = 0.46 respectively). Also, the mean antibody titer after the third stage was 98.8 ± 61 u/l in group A and 86.2 ± 49 u/l in group B where the difference between two groups was not statistically significant (P = 0.38). Side effects resulted from levamisole was not observed in any of patients in group A. Conclusion: According to the results it is possible to express that levamisole pill could be used as a proper adjuvant in improving the response of hepatitis B vaccination in patients suffering from CKD. However, further studies in this field are recommended according to the lack of significant difference between two groups for confirming above mentioned point.

Keywords